GAITHERSBURG, Md., Sept. 8 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it has filled three newly established
leadership roles within its growing organization with senior industry experts,
and has promoted Kevin Rooney to vice president, oncology sales and marketing.
Those joining MedImmune in new roles include Kevin McNelly as vice president,
supply chain operations, James Miller as vice president, international,
business analysis and new products, and Mauricio Vargas-Cortes, Ph.D. as vice
president, project management.
"Bolstering our senior leadership with seasoned industry professionals
from within and outside of MedImmune directly supports our ability to
successfully deliver on our long-term plans for the business," said David M.
Mott, chief executive officer and president. "These individuals have the
skills and talent to complement our existing management team as we provide
commercial and product development support to assure continued growth of our
leading products, seek to bring to market new and improved products, elevate
science within the company, and address our additional five-year strategic
Kevin McNelly was appointed vice president, supply chain operations in
July 2005. In this role, he leads MedImmune's supply chain activities, and is
responsible for the department's overall strategic direction, emphasizing
continued operational integration and development of scalable, customer-
focused solutions. Mr. McNelly has more than 17 years of experience in global
operations management including manufacturing, logistics and distribution,
purchasing, information technology and supply chain management across multiple
industries. Immediately prior to joining MedImmune, Mr. McNelly was vice
president, solution management for Manugistics. He began his career at The
Clorox Company and went on to hold increasingly responsible positions at Smith
& Nephew, Avon and Barr Laboratories. Mr. McNelly holds a bachelor's degree
in mechanical engineering from the Rose-Hulman Institute of Technology in
As vice president of international, business analysis and new products,
James Miller will be responsible for setting the strategic direction for
MedImmune in international markets, supporting the commercialization efforts
of current and future products through business analyses, as well as leading
the commercial development of new products from research to launch. Mr.
Miller recently joined MedImmune from KTM Consulting where he served as
executive director, international management and strategic planning. Prior to
joining KTM, he worked for Abbott Laboratories for 12 years in several
positions of increased responsibility including vice president, international
marketing and business development, vice president/regional director, Europe,
and general manager, Abbott Korea. Mr. Miller holds a bachelor's degree in
accounting from Hillsdale College in Michigan, and he is a certified public
Dr. Mauricio Vargas-Cortes joined MedImmune as vice president, project
management in August 2005. In this position, he is responsible for the
company's project planning and alliance management efforts, as well as guiding
the organization's ongoing development and implementation of project
management processes. Prior to joining MedImmune, Dr. Vargas-Cortes held a
number of project management and clinical development positions with Eli Lilly
and Company, and worked at GlaxoSmithKline for eight years, holding positions
of increasing responsibility. His background includes research positions at
the Immunobiology Research Institute and the University of Massachusetts. Dr.
Vargas-Cortes received bachelor of science degrees in microbiology and biology
from the University of Los Andes in Bogota, Colombia and his Ph.D. in
immunology from the University of Stockholm in Sweden.
Kevin Rooney, newly named vice president, oncology sales and marketing
served as MedImmune's senior director of marketing for Synagis prior to his
promotion in July 2005. In his new position, he will be responsible for
strategic oversight of the sales and marketing organization for MedImmune's
marketed oncology product, Ethyol. Prior to joining MedImmune in July 2003,
Mr. Rooney worked for Bristol-Myers Squibb Company, where he held a number of
increasingly responsible positions in both sales and marketing management. He
also had held various positions at Glaxo Wellcome Inc., Burroughs Wellcome
Company and The Upjohn Company. Mr. Rooney received his master's degree in
management from Northwestern University and his bachelor's degree from the
University of Virginia.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With approximately 2,000 employees
worldwide, MedImmune is headquartered in Maryland. For more information,
visit the company's website at http://www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in MedImmune's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
Jamie Lacey, +1-301-398-4035
both of MedImmune, Inc.